274 related articles for article (PubMed ID: 23396049)
1. Uncovering the molecular secrets of inflammatory breast cancer biology: an integrated analysis of three distinct affymetrix gene expression datasets.
Van Laere SJ; Ueno NT; Finetti P; Vermeulen P; Lucci A; Robertson FM; Marsan M; Iwamoto T; Krishnamurthy S; Masuda H; van Dam P; Woodward WA; Viens P; Cristofanilli M; Birnbaum D; Dirix L; Reuben JM; Bertucci F
Clin Cancer Res; 2013 Sep; 19(17):4685-96. PubMed ID: 23396049
[TBL] [Abstract][Full Text] [Related]
2. Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival.
Bertucci F; Ueno NT; Finetti P; Vermeulen P; Lucci A; Robertson FM; Marsan M; Iwamoto T; Krishnamurthy S; Masuda H; Van Dam P; Woodward WA; Cristofanilli M; Reuben JM; Dirix L; Viens P; Symmans WF; Birnbaum D; Van Laere SJ
Ann Oncol; 2014 Feb; 25(2):358-65. PubMed ID: 24299959
[TBL] [Abstract][Full Text] [Related]
3. Systems biology analysis reveals NFAT5 as a novel biomarker and master regulator of inflammatory breast cancer.
Remo A; Simeone I; Pancione M; Parcesepe P; Finetti P; Cerulo L; Bensmail H; Birnbaum D; Van Laere SJ; Colantuoni V; Bonetti F; Bertucci F; Manfrin E; Ceccarelli M
J Transl Med; 2015 May; 13():138. PubMed ID: 25928084
[TBL] [Abstract][Full Text] [Related]
4. NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers.
Bertucci F; Rypens C; Finetti P; Guille A; Adélaïde J; Monneur A; Carbuccia N; Garnier S; Dirix P; Gonçalves A; Vermeulen P; Debeb BG; Wang X; Dirix L; Ueno NT; Viens P; Cristofanilli M; Chaffanet M; Birnbaum D; Van Laere S
Mol Oncol; 2020 Mar; 14(3):504-519. PubMed ID: 31854063
[TBL] [Abstract][Full Text] [Related]
5. Genomic and expression analysis of microdissected inflammatory breast cancer.
Woodward WA; Krishnamurthy S; Yamauchi H; El-Zein R; Ogura D; Kitadai E; Niwa S; Cristofanilli M; Vermeulen P; Dirix L; Viens P; van Laere S; Bertucci F; Reuben JM; Ueno NT
Breast Cancer Res Treat; 2013 Apr; 138(3):761-72. PubMed ID: 23568481
[TBL] [Abstract][Full Text] [Related]
6. Inflammatory breast cancer cells are characterized by abrogated TGFβ1-dependent cell motility and SMAD3 activity.
Rypens C; Marsan M; Van Berckelaer C; Billiet C; Melis K; Lopez SP; van Dam P; Devi GR; Finetti P; Ueno NT; Bertucci F; Dirix P; Neven P; Vermeulen P; Dirix L; Van Laere SJ
Breast Cancer Res Treat; 2020 Apr; 180(2):385-395. PubMed ID: 32043194
[TBL] [Abstract][Full Text] [Related]
7. Comparison of molecular profile in triple-negative inflammatory and non-inflammatory breast cancer not of mesenchymal stem-like subtype.
Funakoshi Y; Wang Y; Semba T; Masuda H; Hout D; Ueno NT; Wang X
PLoS One; 2019; 14(9):e0222336. PubMed ID: 31532791
[TBL] [Abstract][Full Text] [Related]
8. High-resolution comparative genomic hybridization of inflammatory breast cancer and identification of candidate genes.
Bekhouche I; Finetti P; Adelaïde J; Ferrari A; Tarpin C; Charafe-Jauffret E; Charpin C; Houvenaeghel G; Jacquemier J; Bidaut G; Birnbaum D; Viens P; Chaffanet M; Bertucci F
PLoS One; 2011 Feb; 6(2):e16950. PubMed ID: 21339811
[TBL] [Abstract][Full Text] [Related]
9. Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC.
Iwase T; Harano K; Masuda H; Kida K; Hess KR; Wang Y; Dirix L; Van Laere SJ; Lucci A; Krishnamurthy S; Woodward WA; Layman RM; Bertucci F; Ueno NT
BMC Cancer; 2020 May; 20(1):430. PubMed ID: 32423453
[TBL] [Abstract][Full Text] [Related]
10. Relapse-free survival in breast cancer patients is associated with a gene expression signature characteristic for inflammatory breast cancer.
Van Laere S; Beissbarth T; Van der Auwera I; Van den Eynden G; Trinh XB; Elst H; Van Hummelen P; van Dam P; Van Marck E; Vermeulen P; Dirix L
Clin Cancer Res; 2008 Nov; 14(22):7452-60. PubMed ID: 19010862
[TBL] [Abstract][Full Text] [Related]
11. Genomic profiling of inflammatory breast cancer: a review.
Bertucci F; Finetti P; Vermeulen P; Van Dam P; Dirix L; Birnbaum D; Viens P; Van Laere S
Breast; 2014 Oct; 23(5):538-45. PubMed ID: 24998451
[TBL] [Abstract][Full Text] [Related]
12. Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer.
Iwamoto T; Bianchini G; Qi Y; Cristofanilli M; Lucci A; Woodward WA; Reuben JM; Matsuoka J; Gong Y; Krishnamurthy S; Valero V; Hortobagyi GN; Robertson F; Symmans WF; Pusztai L; Ueno NT
Breast Cancer Res Treat; 2011 Feb; 125(3):785-95. PubMed ID: 21153052
[TBL] [Abstract][Full Text] [Related]
13. Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers.
Masuda H; Baggerly KA; Wang Y; Iwamoto T; Brewer T; Pusztai L; Kai K; Kogawa T; Finetti P; Birnbaum D; Dirix L; Woodward WA; Reuben JM; Krishnamurthy S; Symmans W; Van Laere SJ; Bertucci F; Hortobagyi GN; Ueno NT
Breast Cancer Res; 2013 Nov; 15(6):R112. PubMed ID: 24274653
[TBL] [Abstract][Full Text] [Related]
14. MARCKS protein overexpression in inflammatory breast cancer.
Manai M; Thomassin-Piana J; Gamoudi A; Finetti P; Lopez M; Eghozzi R; Ayadi S; Lamine OB; Manai M; Rahal K; Charafe-Jauffret E; Jacquemier J; Viens P; Birnbaum D; Boussen H; Chaffanet M; Bertucci F
Oncotarget; 2017 Jan; 8(4):6246-6257. PubMed ID: 28009981
[TBL] [Abstract][Full Text] [Related]
15. Gene expression profiling identifies molecular subtypes of inflammatory breast cancer.
Bertucci F; Finetti P; Rougemont J; Charafe-Jauffret E; Cervera N; Tarpin C; Nguyen C; Xerri L; Houlgatte R; Jacquemier J; Viens P; Birnbaum D
Cancer Res; 2005 Mar; 65(6):2170-8. PubMed ID: 15781628
[TBL] [Abstract][Full Text] [Related]
16. Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy.
Bertucci F; Finetti P; Rougemont J; Charafe-Jauffret E; Nasser V; Loriod B; Camerlo J; Tagett R; Tarpin C; Houvenaeghel G; Nguyen C; Maraninchi D; Jacquemier J; Houlgatte R; Birnbaum D; Viens P
Cancer Res; 2004 Dec; 64(23):8558-65. PubMed ID: 15574762
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of patients with inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes: A population-based study from the SEER program.
Li J; Xia Y; Wu Q; Zhu S; Chen C; Yang W; Wei W; Sun S
Oncotarget; 2017 Jul; 8(30):49370-49379. PubMed ID: 28472761
[TBL] [Abstract][Full Text] [Related]
18. Interferon-induced transmembrane protein 1 (IFITM1) overexpression enhances the aggressive phenotype of SUM149 inflammatory breast cancer cells in a signal transducer and activator of transcription 2 (STAT2)-dependent manner.
Ogony J; Choi HJ; Lui A; Cristofanilli M; Lewis-Wambi J
Breast Cancer Res; 2016 Feb; 18(1):25. PubMed ID: 26897526
[TBL] [Abstract][Full Text] [Related]
19. High serum miR-19a levels are associated with inflammatory breast cancer and are predictive of favorable clinical outcome in patients with metastatic HER2+ inflammatory breast cancer.
Anfossi S; Giordano A; Gao H; Cohen EN; Tin S; Wu Q; Garza RJ; Debeb BG; Alvarez RH; Valero V; Hortobagyi GN; Calin GA; Ueno NT; Woodward WA; Reuben JM
PLoS One; 2014; 9(1):e83113. PubMed ID: 24416156
[TBL] [Abstract][Full Text] [Related]
20. Whole-genome sequencing of phenotypically distinct inflammatory breast cancers reveals similar genomic alterations to non-inflammatory breast cancers.
Li X; Kumar S; Harmanci A; Li S; Kitchen RR; Zhang Y; Wali VB; Reddy SM; Woodward WA; Reuben JM; Rozowsky J; Hatzis C; Ueno NT; Krishnamurthy S; Pusztai L; Gerstein M
Genome Med; 2021 Apr; 13(1):70. PubMed ID: 33902690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
